August 25, 2026 (View All Issues)
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
First-line treatment with darovasertib plus crizotinib significantly improved progression-free survival and response rates compared with investigator’s choice of treatment in patients with HLA-A2–negative metastatic uveal melanoma, according to primary results from the phase IIb portion of the
A few weeks ago, a friend in the United States reached out to me about her sister in Rwanda, a woman in her 40s with no history of smoking. Her chest pain had progressively worsened to the point of becoming unbearable. CT imaging revealed a concerning lung mass highly suggestive of malignancy. One...When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase II PYNNACLE trial presented at the 2026 ASCO Breakthrough meeting in Singapore.
The analysis was...
HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer
A human epidermal growth factor receptor 2 (HER2)–targeted regimen achieved high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from the single-arm phase II neoPICD trial. The findings were highlighted during a...
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
Adding the PD-L1 inhibitor durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance therapy delayed high-risk events and improved cystectomy-free survival in patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), according to expanded analyses from the phase...
Cancer Epidemiologist Joseph F. Fraumeni, Jr, MD, Dies at 93
The oncology community is mourning the loss of renowned physician-scientist and cancer epidemiologist Joseph F. Fraumeni, Jr, MD, who died on June 22, 2026, at the age of 93. During a career spanning more than 5 decades at the National Cancer Institute (NCI), Dr. Fraumeni fundamentally changed the...
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
“The future of cancer therapy lies in rational combinations that harness the immune system while preserving patient quality of life.” —Vincent T. DeVita, MD
The treatment landscape for relapsed/refractory (R/R) multiple myeloma continues to evolve rapidly as T-cell–redirecting bispecific...
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Guest Editor’s Note: Cancer and its treatments often contribute to troubling symptoms, including fatigue, which has been correlated with poor treatment-related outcomes, including overall survival, in patients with cancer. Growing evidence indicates that mind-body therapies such as meditation,...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Our data on a triplet combination of chemotherapy, immune checkpoint inhibitors, and targeted therapy (ICTriplex) in advanced and refractory malignancies were presented in June at the 2026 ASCO Breakthrough Conference in Singapore.
ICTriplex is a therapeutic strategy; it is not a single specific ...
Lori J. Pierce, MD, FASCO, Named Distinguished University Professor, University of Michigan
University of Michigan (U-M) Professor Lori J. Pierce, MD, is one of six U-M faculty members recognized for their outstanding teaching and service with one of the university’s prestigious honors, the Distinguished University Professorship.
The U-M Board of Regents recently approved the...
